Lyell Immunopharma, Inc. (LYEL)

Market Cap	505.53M +194.3%
Revenue (ttm)	36,000 -41.0%
Net Income	-274.45M
EPS	-16.06
Shares Out	23.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,911
Open	21.16
Previous Close	21.21
Day's Range	21.16 - 22.66
52-Week Range	7.65 - 45.00
Beta	-0.07
Analysts	Strong Buy
Price Target	27.25 (+26.33%)
Earnings Date	May 12, 2026

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: LYEL
• Website: https://www.lyell.com

Financial Performance

In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for LYEL stock is "Strong Buy." The 12-month stock price target is $27.25, which is an increase of 26.33% from the latest price.

Price Target

$27.25

(26.33% upside)

Analyst Consensus: Strong Buy